Bjørn Guldvog, Deputy Director General of the Norwegian Directorate of Health, recently made the following statement in response to a published study indicating the cancer drug Rituximab may be an effective treatment for ME: "I think that we have not cared for people with ME to a great enough extent. I think it is correct to say that we have not established proper health care services for these people, and I regret that."
Other nations need to follow Norways's example.
Along with an apology, we ask the US to:
1. Double the current NIH funding for extramural research annually until it achieves parity with funding for similarly debilitating chronic diseases like Multiple Sclerosis. Priority should be given to research on biomarkers and potential pathogens as well as clinical trials.
2. Take down information on the CDC's CFS website stating testing for pathogens and biomarkers is "experimental and theoretical" and that GET and CBT are appropriate treatments.